deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT04379518

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

Sponsor: AIM ImmunoTech Inc.

Conditions Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions Recombinant Interferon Alfa-2b Rintatolimod
Updated 16 times since 2020 Last updated: Jan 9, 2026 Started: Nov 17, 2020 Primary completion: Mar 15, 2023 Completion: Mar 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from AIM ImmunoTech Inc.

More terminations from AIM ImmunoTech Inc.

Other Hematopoietic and Lymphoid Cell Neoplasm trials with similar outcome

Browse all Hematopoietic and Lymphoid Cell Neoplasm trials

A PHASE1/PHASE2 clinical study on Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, this trial is terminated or withdrawn. The trial is conducted by AIM ImmunoTech Inc. and has accumulated 16 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Suspended → Terminated

  2. Sep 2024 — Feb 2026 [monthly]

    Suspended PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  5. Apr 2022 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jan 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  10. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  11. Jun 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AIM ImmunoTech Inc.
  • National Cancer Institute (NCI)
  • Roswell Park Cancer Institute
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations